> For the complete documentation index, see [llms.txt](https://www.parapathology.com/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.parapathology.com/clippings/lfabp-liver-fatty-acid-binding-protein.md).

# LFABP: Liver Fatty Acid Binding Protein

Comprehensive diagnostic pathology digest on Liver Fatty Acid Binding Protein (LFABP / FABP1) immunohistochemistry. Covers physiological expression under HNF1A transcriptional control, diagnostic util

Diagnostic immunohistochemistry profile, subtyping algorithms, and diagnostic pitfalls for **Liver Fatty Acid Binding Protein (LFABP / FABP1)** based on [PathologyOutlines: LFABP](https://www.pathologyoutlines.com/topic/stainsLFABP.html) and international hepatopathology consensus guidelines.

***

## Executive Overview & Molecular Biology

| Feature                             | Specification                                                                                                                                                                  |
| ----------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| **Gene Symbol**                     | *FABP1* (HGNC: 3555; Entrez: 2168; Ensembl: ENSG00000163586)                                                                                                                   |
| **Chromosomal Locus**               | Chromosome 2p11.2                                                                                                                                                              |
| **Protein Name**                    | Liver-type Fatty Acid Binding Protein (L-FABP, FABP1, Z-protein)                                                                                                               |
| **Molecular Mass**                  | \~14–15 kDa (127 amino acids)                                                                                                                                                  |
| **Primary Upstream Regulator**      | **HNF1A** (Hepatocyte Nuclear Factor 1-alpha, chromosome 12q24.31)                                                                                                             |
| **Normal Subcellular Localization** | Diffuse **cytoplasmic and nuclear** staining                                                                                                                                   |
| **Physiological Function**          | Intracellular carrier of long-chain fatty acids, eicosanoids, and bile acids; facilitates hepatic lipid transport, fatty acid β-oxidation, and protection against lipotoxicity |
| **Key Diagnostic Indication**       | **Complete loss of expression** is the defining diagnostic hallmark of **HNF1A-inactivated hepatocellular adenoma (H-HCA)**                                                    |

***

## Normal Tissue Expression

LFABP is abundantly expressed in tissues with high fatty acid uptake and metabolism:

* **Liver:** Strong, diffuse, homogeneous cytoplasmic and nuclear positivity in **normal hepatocytes** throughout all zones (Zone 1 through Zone 3). *Biliary epithelial cells (cholangiocytes), Kupffer cells, and vascular endothelial cells are negative.*
* **Kidney:** Strong positivity in **renal proximal tubular epithelial cells** (pars convoluta and pars recta). Distal tubules, collecting ducts, and glomeruli are negative or trace.
* **Gastrointestinal Tract:** Moderate-to-strong cytoplasmic positivity in mucosal enterocytes of the **duodenum, jejunum, ileum, and cecum/colon** (decreasing along the craniocaudal axis). Gastric foveolar epithelium is normally negative (becomes positive in intestinal metaplasia).
* **Alveolar / Bronchial:** Negative.

```
┌────────────────────────────────────────────────────────────────────────────────────────┐
│                        NORMAL TISSUE INTERNAL CONTROLS FOR LFABP                      │
└────────────────────────────────────────────────────────────────────────────────────────┘
  Normal Liver Parenchyma: 
    [ Hepatocyte Cytoplasm + Nucleus ]  ──► Strong Diffuse Positivity (3+)
    [ Bile Ducts / Kupffer Cells ]     ──► Internal Negative Control (0)
  
  Adjacent Renal Parenchyma:
    [ Proximal Convoluted Tubules ]     ──► Strong Positive Control (3+)
    [ Distal Tubules / Glomeruli ]      ──► Internal Negative Control (0)
```

***

## Diagnostic Applications in Surgical Pathology

### 1. Hepatocellular Adenoma (HCA) Subtyping (Bordeaux / WHO Classification)

Hepatocellular adenomas are benign liver neoplasms classified into molecular and clinicopathological subgroups. LFABP immunohistochemistry serves as an indispensable primary tier in the standard HCA diagnostic panel:

```
                                HEPATIC ADENOMA WORKUP
                                          │
                         Immunohistochemical Panel:
               [ LFABP, Serum Amyloid A (SAA) / CRP, Glutamine Synthetase (GS), β-Catenin ]
                                          │
        ┌─────────────────────────────────┼─────────────────────────────────┐
        ▼                                 ▼                                 ▼
   LFABP ABSENT                      SAA / CRP (+)                  β-Catenin Nuclear (+)
  (Complete Loss)                   (Strong Diffuse)                 & GS Diffuse Strong
        │                                 │                                 │
        ▼                                 ▼                                 ▼
    HNF1A-Inactivated              Inflammatory HCA                 β-Catenin-Mutated
      HCA (H-HCA)                      (I-HCA)                          HCA (B-HCA)
   • 30–40% of HCAs                • 40–50% of HCAs                 • 10–15% of HCAs
   • Diffuse steatosis             • Systemic inflammation          • High risk of HCC
   • Biallelic HNF1A mut           • IL6ST / STAT3 activation         transformation
   • Negligible HCC risk           • 10% co-mutate β-cat (B-IHCA)   • Exon 3 vs 7/8 mutations
```

#### Diagnostic Characteristics of H-HCA:

* **Pathognomonic Staining:** **Complete absence (loss of expression)** of LFABP in the neoplastic hepatocytes.
* **Mandatory Internal Control:** Non-neoplastic background liver parenchyma adjacent to or entrapped within the biopsy must demonstrate strong, diffuse cytoplasmic/nuclear LFABP positivity. If background liver is unstained, the run is analytically invalid.
* **Histomorphological Correlates:** Markedly diffuse microvesicular and macrovesicular steatosis (>80% of cases), lack of significant nuclear atypia, absence of pseudoglands or pseudoacini, and no thick trabeculae.
* **Clinical Significance:** H-HCA carries the lowest rate of malignant transformation (<1%) and minimal bleeding risk compared to other subtypes. Frequently observed in patients with maturity-onset diabetes of the young type 3 (MODY3) or familial adenomatosis.

### 2. Differential Diagnosis: Benign Liver Lesions vs. Hepatocellular Carcinoma

| Entity                              | LFABP                           | Glutamine Synthetase (GS)                               | SAA / CRP                | Glypican-3               | CD34 Endothelial                    | Reticulin Framework                             |
| ----------------------------------- | ------------------------------- | ------------------------------------------------------- | ------------------------ | ------------------------ | ----------------------------------- | ----------------------------------------------- |
| **Normal Liver**                    | **Positive (3+)**               | Zone 3 perivenular rim (1–2 cell layers)                | Negative                 | Negative                 | Periportal only                     | Intact (1–2 cell thick plates)                  |
| **Focal Nodular Hyperplasia (FNH)** | **Positive (3+)**               | Characteristic **"map-like" / geographic anastomosing** | Negative                 | Negative                 | Preserved lobular                   | Intact, dystrophic large vessels, central scar  |
| **HNF1A-Inactivated HCA (H-HCA)**   | **ABSENT (0)**                  | Negative or faint non-zonal                             | Negative                 | Negative                 | Minimal patchy                      | Intact (isolated thin plates, no portal tracts) |
| **Inflammatory HCA (I-HCA)**        | **Positive (3+)**               | Negative or perivascular rim                            | **Diffuse Strong (+)**   | Negative                 | Sinusoidal patchy                   | Intact, ductular reaction, dystrophic vessels   |
| **β-Catenin Mutated HCA (B-HCA)**   | **Positive (3+)**               | **Strong diffuse homogeneous**                          | Negative (unless B-IHCA) | Negative                 | Patchy                              | Intact or focal loss                            |
| **Well-Differentiated HCC**         | **Variable (Lost in \~20–30%)** | Often diffuse strong (if β-cat altered)                 | Variable                 | **Positive in \~60–70%** | **Diffuse diffuse capillarization** | **Fragmented or completely absent**             |

***

## Critical Diagnostic Pitfalls

> \[!CAUTION] **LFABP Loss Does NOT Equal Benignity:** Downregulation or complete loss of LFABP is observed in **15–30% of hepatocellular carcinomas (HCCs)**, particularly steatohepatitic HCC variants or HCCs arising from *HNF1A*-mutated backgrounds.
>
> **Never diagnose an H-HCA based solely on LFABP loss if any features of malignancy are present:**
>
> 1. Reticulin framework loss (widened cords $\ge 3$ cells, fragmented reticulin meshwork).
> 2. Diffuse sinusoidal capillarization on CD34.
> 3. Nuclear atypia, prominent macronucleoli, or atypical mitotic figures.
> 4. Pseudoacinar/glandular architectural remodeling.
> 5. Diffuse Glypican-3 or HSP70 expression.

### Additional Pitfalls:

* **Patchy or Heterogeneous Staining:** True H-HCA exhibits complete, total loss of LFABP throughout the entire nodule. Heterogeneous, patchy, or mosaic staining should raise suspicion for an alternative HCA subtype, focal clonal escape, or a well-differentiated HCC.
* **Biopsy Sampling Limitation:** Needle biopsies lacking adjacent non-neoplastic liver parenchyma deprive the pathologist of the mandatory internal positive control. If background hepatocytes are absent and the lesion is negative, report as *indeterminate for LFABP evaluation* unless repeat cutting captures non-lesional liver.

***

## Secondary Diagnostic Uses

### 1. Renal Cell Neoplasm Subtyping

Because LFABP is normally expressed in proximal tubules:

* **Clear Cell Renal Cell Carcinoma (ccRCC):** Typically **positive** (cytoplasmic and membranous/nuclear, \~70–85% of cases).
* **Papillary Renal Cell Carcinoma (pRCC):** Frequently **positive** (\~60–80%).
* **Chromophobe Renal Cell Carcinoma (chRCC):** Typically **negative** or only weak, focal positivity.
* **Renal Oncocytoma:** Typically **negative**.
* *Clinical application:* Useful adjunct in challenging oncocytic/eosinophilic renal neoplasms when differentiating eosinophilic ccRCC from chRCC or oncocytoma.

### 2. Gastrointestinal Adenocarcinomas

* Serves as a phenotypic marker of enterocytic differentiation.
* Positive in small intestinal adenocarcinomas and intestinal-type gastric adenocarcinomas; negative in diffuse/signet-ring gastric carcinomas and non-intestinal foregut neoplasms.

***

## Laboratory & Technical Specifications

| Parameter                        | Recommended Specification                                                                                                                                                   |
| -------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **Representative Clones**        | **C-4** (mouse monoclonal, Santa Cruz); **EP224** (rabbit monoclonal); **EPR2189** (rabbit monoclonal, Abcam)                                                               |
| **Antigen Retrieval (HIER)**     | Heat-Induced Epitope Retrieval in **High pH buffer (Tris-EDTA, pH 9.0)** at 95–99°C for 20–30 min                                                                           |
| **Recommended Detection System** | 2-step or 3-step polymer-based horseradish peroxidase (HRP) with DAB chromogen                                                                                              |
| **Positive Control Tissue**      | Normal liver parenchyma (hepatocytes 3+) or normal kidney cortex (proximal tubules 3+)                                                                                      |
| **Negative Control Tissue**      | Tonsil, lymphoid tissue, or omission of primary antibody                                                                                                                    |
| **Quality Reporting Standard**   | Report as: (1) Intact/Retained expression, (2) Complete loss of expression (specifying presence of positive internal control), or (3) Equivocal/Suboptimal internal control |
